Toledo
in inflammation

- Novel, undisclosed target
- Dual action on inflammation
- IBD models show strong activity
- ‘3970 prioritized after Phase 1



Galápagos

Restoring the immune imbalance



Galápagos

Efficacy in arthritis models with ‘3970

CIA MODEL



PSA MODEL
IL-23-induced



Robust efficacy demonstrated across preclinical models of arthritis with 2nd gen Toledo

Source: internal data on file

Galápagos

TOLEDO's expanding family

Different selectivity profiles

- '3312 pan-TOL
- '3970 TOL2 & TOL3 selective

Third candidate nominated

- '4399 TOL3 selective



Galápagos

Toledo: robust activity in *in vivo* models



green: preclinical activity; orange: insufficient preclinical activity
Note: '3312 no longer actively developed

Galápagos